Developer docs
API playgroundTry for free, no card

Search company profiles

Lumea

Full company profile

uuid0005jtu

Namestring
Lumea
Legal namestring
Lumea
Websiteurl
lumea.net
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Lumea is a U.S.-headquartered (Lehi, Utah) digital pathology company founded in 2013 that sells a specialty-specific platform covering the full diagnostic workflow from biopsy to final report, serving urology, dermatopathology, and gastroenterology laboratories. The platform is built around four components: the FDA 510(k)-cleared IMS Viewer+ for primary clinical diagnosis, BxLink (a digital pathology-enabled LIS for case management and molecular test ordering), a proprietary tissue-handling portfolio (BxBoard, BxChip, BxCamera, BxFrame, FocalRing) that improves specimen quality at the point of collection, and an open Partner Marketplace integrating third-party AI tools, molecular tests, scanners, and lab technology. The company reports more than 40% share of the U.S. outpatient prostate cancer diagnostics market and a customer base of hundreds of labs ranging from single-pathologist offices to nationwide networks, with GI Alliance (the nation's largest GI network) cited as a flagship deployment.

Lumea generates revenue through a mix of recurring software subscriptions (IMS Viewer+, BxLink), hardware and consumables sales (BxBoard, BxChip, BxCamera tissue-handling products), and a marketplace model that monetizes third-party AI and molecular test integrations within the diagnostic workspace. Go-to-market is primarily enterprise field sales with a 'Request Information' demo-led acquisition motion and 3-9 month implementation timelines, supplemented by a North America e-commerce shop, a separate Europe catalog, and an international distributor network. Pricing is quote-based and not publicly disclosed, with the company claiming typical customer ROI within three months of full-platform implementation.

Strategically, Lumea has aggressively expanded its AI and workflow footprint through partnerships with Voicebrook (voice-enabled documentation, announced 2026-02-11), Primaa (Cleo Skin AI for dermatopathology, 2026-03-24), and AIxMed (AIxURO urine cytology AI for urology, 2025-05-30), positioning itself as a platform-of-record rather than a point viewer. Recognition on Inc. 5000, Fast 500, Fast 50, and a favorable KLAS Research customer satisfaction finding versus traditional imaging vendors underscore commercial traction, though no revenue figure, funding history, or headcount detail beyond the 11-50 range is disclosed in the available data.

Short descriptiontext

Lumea is a Lehi, Utah-based digital pathology company that provides an FDA-cleared platform covering biopsy-to-diagnosis for urology, dermatopathology, and gastroenterology labs, serving hundreds of practices including the nation's largest GI network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLehi, United States
HQ citystring
Lehi
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology platform, whole slide imaging, pathology laboratory software, biopsy tissue technology, diagnostic AI marketplace
Industry4 codes
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAHAAAO
Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Custom Computer Programming Services541511
  • Computer Systems Design and Related Services54151
SIC code3 codes
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Digital Pathology Software and Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Digital Pathology Software Platform
TypeSubscription Recurring
Description

Subscription-based revenue from FDA-cleared IMS Viewer+ platform providing whole slide imaging diagnostic capabilities. Labs recover investment within three months through efficiency gains, reduced shipping/courier costs, lower slide storage expenses, and fewer repeat procedures.

lumeadigital.com:443
2Tissue-Handling Technology
TypeHardware Sales
Description

Hardware and consumables revenue from BxBoard, BxChip, BxCamera, and related tissue technology products. Provides immediate ROI within three months of implementation through improved specimen quality and reduced diagnostic errors.

lumeadigital.com:443
3Laboratory Information System (BxLink)
TypeSubscription Recurring
Description

LIS software revenue for complete case management and molecular test ordering integrated with digital pathology workflow.

lumeadigital.com:443
4Partner Marketplace
TypeMarketplace Commission
Description

Revenue from integration of third-party AI tools and molecular tests into Lumea's platform ecosystem, expanding diagnostic capabilities for pathology labs.

lumeadigital.com:443
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details2 tiers
1Enterprise Full Platform
ModelSubscriptionBilling cadenceAnnual
Notes

Full platform including IMS Viewer+, BxLink, tissue-handling technology, and AI ecosystem integration. ROI achieved within three months for most labs.

lumeadigital.com:443
2Modular/Component-based
ModelHybridBilling cadenceAnnual
Notes

Labs can start with individual components (viewer only, tissue-handling technology only) and scale from there. Suitable for single-pathologist practices to large nationwide networks.

lumeadigital.com:443
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1IMS Viewer+
Description

FDA-cleared digital pathology viewer for primary clinical diagnosis

lumeadigital.com:443
+4 more records
Core offering1 text field

Lumea provides a specialty-specific digital pathology platform covering the full biopsy-to-diagnosis workflow. Its core offerings include the FDA 510(k)-cleared IMS Viewer+ for whole slide imaging, the BxLink digital pathology-enabled LIS, proprietary tissue-handling devices (BxBoard, BxChip, BxCamera, BxFrame), and an open Partner Marketplace that embeds third-party AI, molecular tests, and scanners directly into the diagnostic workspace. The platform is purpose-built for urology, dermatopathology, and gastroenterology practices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 19% increase in cancer detection rates
+3 more records
Product overview1 text field

Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow from biopsy to final report. The platform operates as a unified platform-plus-modules architecture with four core components: (1) IMS Viewer+ - an FDA 510(k)-cleared digital pathology viewer for full diagnostic capability on any device; (2) BxLink - an all-in-one digital pathology-enabled LIS for case management and molecular test ordering; (3) Tissue-handling and histology technology (BxBoard, BxChip, BxCamera) that improves specimen quality and workflow efficiency starting at the point of collection; and (4) An open AI ecosystem via the Partner Marketplace that lets labs integrate AI tools from partners including Paige, Primaa, Mindpeak, and AIRA Matrix directly into the diagnostic workspace. The platform is designed for specialty-specific workflows in urology (particularly prostate cancer diagnostics, supporting over 40% of the U.S. outpatient market), dermatopathology, and gastroenterology.

Product and service7 records
1IMS Viewer+
CategoryDigital Pathology Viewer Software
Description

FDA 510(k)-cleared digital pathology viewer for primary clinical diagnosis using whole slide images. Provides lightning-fast, closest-to-glass performance with seamless access to AI and molecular testing on one screen, compatible with images from all major scanner manufacturers, and configurable for urology, dermatopathology, and gastroenterology workflows.

2BxLink
CategoryLaboratory Information System Software
Description

Digital pathology-enabled Laboratory Information System (LIS) that manages case intake, image routing, AI result integration, molecular test ordering, and report generation in a single workspace for pathology labs; not approved by the FDA for digital primary diagnosis.

3BxBoard
CategoryTissue-Handling Device
Description

Precision tissue collection device for physicians and medical assistants that preserves specimen integrity, minimizes fragmentation, and improves diagnostic yield; available in prostate biopsy ('The Better Biopsy') and bladder (FocalRing) configurations.

4BxCamera
CategoryLab Grossing Technology
Description

Better Grossing lab technology for pathologists' assistants and histotechs that enables digital grossing documentation, reduces errors, accelerates turnaround, and maximizes lab productivity and revenue.

5BxChip
CategoryTissue-Handling Consumable
Description

Prostate tissue collection chip for the laboratory workflow that preserves specimen quality and supports efficient tissue handling during processing.

6BxFrame
CategoryTissue-Handling Device
Description

Gastrointestinal tissue handling technology for improved tissue handling and specimen quality in GI diagnostics.

7Partner Marketplace
CategoryAI and Integrations Marketplace
Description

Open AI ecosystem and marketplace allowing labs to integrate best-in-class AI tools (Paige, Primaa, Mindpeak, AIRA Matrix, AIxMed), molecular tests, scanners, and lab technology partners directly into the diagnostic workspace without changing existing LIS or scanning hardware.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-24
Description

Partnership to integrate Primaa's Cleo Skin AI solution into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin is the first AI tool worldwide designed specifically to assist in diagnosing the four most common skin lesions, offering automated triage, sub-millimeter measurements, and biomarker detection. The open marketplace integration allows labs to adopt the technology without changing their existing LIS or scanning hardware, expanding Lumea's diagnostic ecosystem for dermatology groups.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-11
Description

Strategic partnership integrating Voicebrook's VoiceOver PRO platform with Lumea's digital pathology ecosystem including BxCamera and BxLink. The collaboration enables hands-free documentation, image capture, and structured reporting workflows for pathology labs, spanning from grossing through final sign-out. The integrated voice-enabled solution is now available for laboratories seeking to modernize their pathology operations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-30
Description

Partnership to integrate AIxMed's AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive procedures like cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem serving a significant portion of the U.S. urology market.

4Paige
Strategic tierCoreTypeTechnology or Integration
Description

AI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools for prostate cancer and other applications directly within the diagnostic workspace.

lumeadigital.com:443
Strategic tierCoreTypeTechnology or Integration
Description

AI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.

Strategic tierCoreTypeTechnology or Integration
Description

AI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

GI Alliance, the nation's largest GI network, selected Lumea's Viewer+ to power their digital pathology transition. This represents a flagship partnership with the leading GI network in the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Paige builds AI-enabled digital pathology software for cancer diagnostics, including an FDA-authorized prostate cancer detection tool. Directly comparable to Lumea in serving pathology labs with whole-slide-image workflows and AI integrations; Paige is also a partner in Lumea's marketplace.

TypeDirect peer
Description

Proscia offers a digital pathology platform (Concentriq) used by pathology labs and life sciences organizations for case management, AI integration, and image analysis. Competes head-to-head with Lumea's IMS Viewer+ and BxLink in enabling clinical and research workflows.

TypeDirect peer
Description

Ibex develops AI-powered decision-support tools for pathology (e.g., Galen Prostate, Galen Breast) deployed across pathology networks. Directly comparable as an AI-pathology vendor whose tools integrate into digital pathology workflows similar to Lumea's partner ecosystem.

TypeDirect peer
Description

PathAI provides AI-driven pathology solutions for both clinical diagnostics and biopharma research, including integrated digital pathology workflow tools. Comparable to Lumea in advancing AI-augmented primary diagnosis and partnering with pathology labs.

TypeDirect peer
Description

Indica Labs provides HALO and HALO AI digital pathology image analysis software used by clinical and research pathology labs worldwide. Comparable to Lumea in offering enterprise image-management and AI-integration capabilities for pathology workflows.

TypeDirect peer
Description

Gestalt Diagnostics offers a digital pathology workflow platform (PathFlow) integrating whole-slide imaging, LIS, and AI for pathology labs. Directly comparable to Lumea's IMS Viewer+ and BxLink in providing an integrated viewer and case-management solution.

TypeBroad incumbent
Description

Philips IntelliSite Digital Pathology Solution is an established, broad-line enterprise offering used by large hospital systems. Comparable to Lumea in FDA-cleared whole-slide imaging and LIS integration, but as part of Philips' wider healthcare portfolio rather than a specialty-focused platform.

TypeBroad incumbent
Description

Leica Biosystems, through its Aperio platform, is one of the most entrenched digital pathology scanner and software providers globally. Comparable in providing FDA-cleared viewing and workflow tools, though as a broad-line incumbent with hardware-heavy offerings.

TypeBroad incumbent
Description

Hamamatsu's NanoZoomer whole-slide scanners and NDP.view software are widely deployed in pathology labs. Comparable to Lumea's imaging-infrastructure stack, though as a hardware-led incumbent rather than a specialty workflow platform.

TypeBroad incumbent
Description

Roche's Ventana digital pathology business provides scanners, workflow software, and AI applications for pathology labs. Comparable in offering end-to-end clinical pathology workflows, though as part of Roche Diagnostics' large IVD portfolio rather than a specialty-focused entrant.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumea

Digital Pathology Software and Diagnosticslumea.net

Lumea is a Lehi, Utah-based digital pathology company that provides an FDA-cleared platform covering biopsy-to-diagnosis for urology, dermatopathology, and gastroenterology labs, serving hundreds of practices including the nation's largest GI network.

What Lumea does

Lumea is a U.S.-headquartered (Lehi, Utah) digital pathology company founded in 2013 that sells a specialty-specific platform covering the full diagnostic workflow from biopsy to final report, serving urology, dermatopathology, and gastroenterology laboratories. The platform is built around four components: the FDA 510(k)-cleared IMS Viewer+ for primary clinical diagnosis, BxLink (a digital pathology-enabled LIS for case management and molecular test ordering), a proprietary tissue-handling portfolio (BxBoard, BxChip, BxCamera, BxFrame, FocalRing) that improves specimen quality at the point of collection, and an open Partner Marketplace integrating third-party AI tools, molecular tests, scanners, and lab technology. The company reports more than 40% share of the U.S. outpatient prostate cancer diagnostics market and a customer base of hundreds of labs ranging from single-pathologist offices to nationwide networks, with GI Alliance (the nation's largest GI network) cited as a flagship deployment.

Lumea generates revenue through a mix of recurring software subscriptions (IMS Viewer+, BxLink), hardware and consumables sales (BxBoard, BxChip, BxCamera tissue-handling products), and a marketplace model that monetizes third-party AI and molecular test integrations within the diagnostic workspace. Go-to-market is primarily enterprise field sales with a 'Request Information' demo-led acquisition motion and 3-9 month implementation timelines, supplemented by a North America e-commerce shop, a separate Europe catalog, and an international distributor network. Pricing is quote-based and not publicly disclosed, with the company claiming typical customer ROI within three months of full-platform implementation.

Strategically, Lumea has aggressively expanded its AI and workflow footprint through partnerships with Voicebrook (voice-enabled documentation, announced 2026-02-11), Primaa (Cleo Skin AI for dermatopathology, 2026-03-24), and AIxMed (AIxURO urine cytology AI for urology, 2025-05-30), positioning itself as a platform-of-record rather than a point viewer. Recognition on Inc. 5000, Fast 500, Fast 50, and a favorable KLAS Research customer satisfaction finding versus traditional imaging vendors underscore commercial traction, though no revenue figure, funding history, or headcount detail beyond the 11-50 range is disclosed in the available data.

Lumea firmographics

Firmographics
Name
Lumea
Legal name
Lumea
Website
https://lumea.net
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Lumea is a Lehi, Utah-based digital pathology company that provides an FDA-cleared platform covering biopsy-to-diagnosis for urology, dermatopathology, and gastroenterology labs, serving hundreds of practices including the nation's largest GI network.
Ownership category
akta.pro rank

Lumea industry classification

Industry
Product category
Digital Pathology Software and Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
SIC
Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAHAAAO
Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Digital pathology platform
  • Whole slide imaging
  • Pathology laboratory software
  • Biopsy tissue technology
  • Diagnostic AI marketplace

Where Lumea is headquartered

Location

Headquarters

HQ city
Lehi
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lumea business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Digital Pathology Software Platform: Subscription-based revenue from FDA-cleared IMS Viewer+ platform providing whole slide imaging diagnostic capabilities. Labs recover investment within three months through efficiency gains, reduced shipping/courier costs, lower slide storage expenses, and fewer repeat procedures.
  2. Tissue-Handling Technology: Hardware and consumables revenue from BxBoard, BxChip, BxCamera, and related tissue technology products. Provides immediate ROI within three months of implementation through improved specimen quality and reduced diagnostic errors.
  3. Laboratory Information System (BxLink): LIS software revenue for complete case management and molecular test ordering integrated with digital pathology workflow.
  4. Partner Marketplace: Revenue from integration of third-party AI tools and molecular tests into Lumea's platform ecosystem, expanding diagnostic capabilities for pathology labs.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise Full Platform
HybridAnnualModular/Component-based

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Lumea product offering

Product offering

Core offering

Lumea provides a specialty-specific digital pathology platform covering the full biopsy-to-diagnosis workflow. Its core offerings include the FDA 510(k)-cleared IMS Viewer+ for whole slide imaging, the BxLink digital pathology-enabled LIS, proprietary tissue-handling devices (BxBoard, BxChip, BxCamera, BxFrame), and an open Partner Marketplace that embeds third-party AI, molecular tests, and scanners directly into the diagnostic workspace. The platform is purpose-built for urology, dermatopathology, and gastroenterology practices.

Product overview

Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow from biopsy to final report. The platform operates as a unified platform-plus-modules architecture with four core components: (1) IMS Viewer+ - an FDA 510(k)-cleared digital pathology viewer for full diagnostic capability on any device; (2) BxLink - an all-in-one digital pathology-enabled LIS for case management and molecular test ordering; (3) Tissue-handling and histology technology (BxBoard, BxChip, BxCamera) that improves specimen quality and workflow efficiency starting at the point of collection; and (4) An open AI ecosystem via the Partner Marketplace that lets labs integrate AI tools from partners including Paige, Primaa, Mindpeak, and AIRA Matrix directly into the diagnostic workspace. The platform is designed for specialty-specific workflows in urology (particularly prostate cancer diagnostics, supporting over 40% of the U.S. outpatient market), dermatopathology, and gastroenterology.

Differentiator

Problem solved

Functional benefit

Brands

  • IMS Viewer+: FDA-cleared digital pathology viewer for primary clinical diagnosis
  • BxLink
  • BxBoard
  • BxCamera
  • BxChip

Products and services

  • IMS Viewer+ FDA 510(k)-cleared digital pathology viewer for primary clinical diagnosis using whole slide images. Provides lightning-fast, closest-to-glass performance with seamless access to AI and molecular testing on one screen, compatible with images from all major scanner manufacturers, and configurable for urology, dermatopathology, and gastroenterology workflows.
  • BxLink Digital pathology-enabled Laboratory Information System (LIS) that manages case intake, image routing, AI result integration, molecular test ordering, and report generation in a single workspace for pathology labs; not approved by the FDA for digital primary diagnosis.
  • BxBoard Precision tissue collection device for physicians and medical assistants that preserves specimen integrity, minimizes fragmentation, and improves diagnostic yield; available in prostate biopsy ('The Better Biopsy') and bladder (FocalRing) configurations.
  • BxCamera Better Grossing lab technology for pathologists' assistants and histotechs that enables digital grossing documentation, reduces errors, accelerates turnaround, and maximizes lab productivity and revenue.
  • BxChip Prostate tissue collection chip for the laboratory workflow that preserves specimen quality and supports efficient tissue handling during processing.
  • BxFrame Gastrointestinal tissue handling technology for improved tissue handling and specimen quality in GI diagnostics.
  • Partner Marketplace Open AI ecosystem and marketplace allowing labs to integrate best-in-class AI tools (Paige, Primaa, Mindpeak, AIRA Matrix, AIxMed), molecular tests, scanners, and lab technology partners directly into the diagnostic workspace without changing existing LIS or scanning hardware.

Quantifiable outcome

  • 19% increase in cancer detection rates
  • +3 more outcomes

Companies that use Lumea

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Lumea technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability3 records

Feature8 records

Lumea partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and flagship.

  • PrimaacoreTechnology or Integration · 24 March 2026Partnership to integrate Primaa's Cleo Skin AI solution into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin is the first AI tool worldwide designed specifically to assist in diagnosing the four most common skin lesions, offering automated triage, sub-millimeter measurements, and biomarker detection. The open marketplace integration allows labs to adopt the technology without changing their existing LIS or scanning hardware, expanding Lumea's diagnostic ecosystem for dermatology groups.
  • VoicebrookcoreTechnology or Integration · 11 February 2026Strategic partnership integrating Voicebrook's VoiceOver PRO platform with Lumea's digital pathology ecosystem including BxCamera and BxLink. The collaboration enables hands-free documentation, image capture, and structured reporting workflows for pathology labs, spanning from grossing through final sign-out. The integrated voice-enabled solution is now available for laboratories seeking to modernize their pathology operations.
  • AIxMedcoreTechnology or Integration · 30 May 2025Partnership to integrate AIxMed's AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive procedures like cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem serving a significant portion of the U.S. urology market.
  • PaigecoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools for prostate cancer and other applications directly within the diagnostic workspace.
  • MindpeakcoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.
  • AIRA MatrixcoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.
  • GI AllianceflagshipStrategic or Co-development PartnerGI Alliance, the nation's largest GI network, selected Lumea's Viewer+ to power their digital pathology transition. This represents a flagship partnership with the leading GI network in the United States.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Lumea competitors and assessment

Company assessment

Direct peers

  • Paige.AI: Paige builds AI-enabled digital pathology software for cancer diagnostics, including an FDA-authorized prostate cancer detection tool. Directly comparable to Lumea in serving pathology labs with whole-slide-image workflows and AI integrations; Paige is also a partner in Lumea's marketplace.
  • Proscia: Proscia offers a digital pathology platform (Concentriq) used by pathology labs and life sciences organizations for case management, AI integration, and image analysis. Competes head-to-head with Lumea's IMS Viewer+ and BxLink in enabling clinical and research workflows.
  • Ibex Medical Analytics: Ibex develops AI-powered decision-support tools for pathology (e.g., Galen Prostate, Galen Breast) deployed across pathology networks. Directly comparable as an AI-pathology vendor whose tools integrate into digital pathology workflows similar to Lumea's partner ecosystem.
  • PathAI: PathAI provides AI-driven pathology solutions for both clinical diagnostics and biopharma research, including integrated digital pathology workflow tools. Comparable to Lumea in advancing AI-augmented primary diagnosis and partnering with pathology labs.
  • Indica Labs: Indica Labs provides HALO and HALO AI digital pathology image analysis software used by clinical and research pathology labs worldwide. Comparable to Lumea in offering enterprise image-management and AI-integration capabilities for pathology workflows.
  • Gestalt Diagnostics: Gestalt Diagnostics offers a digital pathology workflow platform (PathFlow) integrating whole-slide imaging, LIS, and AI for pathology labs. Directly comparable to Lumea's IMS Viewer+ and BxLink in providing an integrated viewer and case-management solution.

Broad incumbents

  • Philips (Digital Pathology): Philips IntelliSite Digital Pathology Solution is an established, broad-line enterprise offering used by large hospital systems. Comparable to Lumea in FDA-cleared whole-slide imaging and LIS integration, but as part of Philips' wider healthcare portfolio rather than a specialty-focused platform.
  • Leica Biosystems (Aperio): Leica Biosystems, through its Aperio platform, is one of the most entrenched digital pathology scanner and software providers globally. Comparable in providing FDA-cleared viewing and workflow tools, though as a broad-line incumbent with hardware-heavy offerings.
  • Hamamatsu Photonics (NanoZoomer): Hamamatsu's NanoZoomer whole-slide scanners and NDP.view software are widely deployed in pathology labs. Comparable to Lumea's imaging-infrastructure stack, though as a hardware-led incumbent rather than a specialty workflow platform.
  • Roche (Ventana Digital Pathology): Roche's Ventana digital pathology business provides scanners, workflow software, and AI applications for pathology labs. Comparable in offering end-to-end clinical pathology workflows, though as part of Roche Diagnostics' large IVD portfolio rather than a specialty-focused entrant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Lumea social profiles

Digital presence

Lumea compliance and trust

Trust signal

Compliance3 records

Lumea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumea leadership team

Management profile

Number of profiles

Profiles2 records

Lumea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumea

What does Lumea do?

Lumea provides a specialty-specific digital pathology platform covering the full biopsy-to-diagnosis workflow. Its core offerings include the FDA 510(k)-cleared IMS Viewer+ for whole slide imaging, the BxLink digital pathology-enabled LIS, proprietary tissue-handling devices (BxBoard, BxChip, BxCamera, BxFrame), and an open Partner Marketplace that embeds third-party AI, molecular tests, and scanners directly into the diagnostic workspace. The platform is purpose-built for urology, dermatopathology, and gastroenterology practices.

Is Lumea a public or private company?

Lumea is a private company. It is classified as unknown and is currently operating.

When was Lumea founded?

Lumea was founded in 2014. It employs 51 to 100 people.

Where is Lumea based?

Lumea is headquartered in Lehi, United States, in the North America region.

How does Lumea make money?

Four revenue lines are on record. Digital Pathology Software Platform is the primary driver. The others are tissue-Handling Technology, laboratory Information System (BxLink) and partner Marketplace.

Who are Lumea's main competitors?

Direct peers on record are Paige.AI, Proscia, Ibex Medical Analytics, PathAI, Indica Labs and Gestalt Diagnostics. Broad incumbents are Philips (Digital Pathology), Leica Biosystems (Aperio), Hamamatsu Photonics (NanoZoomer) and Roche (Ventana Digital Pathology).

Does Lumea have an API?

No public API is recorded for Lumea.

What industry is Lumea in?

Lumea's product category is Digital Pathology Software and Diagnostics. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HLACAMAJ, Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireLumea Named a Utah Top Workplace for the Third Consecutive YearLumea was named one of Utah's 2026 Top Workplaces, its third consecutive year on the list based on anonymous employee feedback. The company ranked No. 21 among 35 honorees in the small employer category, with 130 Utah organizations recognized. The awards luncheon was held in Draper on Oct. 22.EIN PresswireLumea Named a Utah Top Workplace for the Third Consecutive YearLumea was named one of Utah's 2026 Top Workplaces, its third consecutive year on the list based on anonymous employee feedback. The company ranked No. 21 among 35 honorees in the small employer category, with 130 Utah organizations recognized. The awards luncheon was held on Oct. 22 in Draper.Business & FinancialLumea Enhances Digital Diagnostic Ecosystem With Nonagen Bioscience's Oncuria® Suite Of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform. The integration includes three assays—Detect, Monitor, and Predict—designed for detection, surveillance, and treatment response assessment. The partnership aims to streamline ordering and connect clinical information within urologists' workflows.EIN PresswireLumea Enhances Digital Diagnostic Ecosystem with Nonagen Bioscience’s Oncuria® Suite of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform, bringing Detect, Monitor, and Predict assays to urologists' workflows. The tests use multiplex urine biomarkers and AI to provide risk assessments, with Detect for new cases, Monitor for surveillance, and Predict for BCG therapy response.EIN PresswireLumea Enhances Digital Diagnostic Ecosystem with Nonagen Bioscience’s Oncuria® Suite of Bladder Cancer TestsLumea integrated Nonagen Bioscience's Oncuria suite of bladder cancer tests into its digital diagnostics platform. The integration includes Detect, Monitor, and Predict assays for bladder cancer detection, surveillance, and treatment response assessment. The partnership aims to streamline ordering and connect clinical information within urologists' workflows.EIN PresswireLumea Named Best New Biopsy Technology Solution in 2026 Medtech Breakthrough AwardsLumea was named Best New Biopsy Technology Solution in the 2026 MedTech Breakthrough Awards, beating thousands of entries. Its BxBoard system reduces cancelled tests by 2.1x and cuts collection containers by 83%. The company also supports 40% of the U.S. outpatient prostate market.EIN PresswireLumea Appoints Former HHS Secretary Michael O. Leavitt as Board ChairmanLumea appointed former HHS Secretary Michael O. Leavitt as board chairman, succeeding founder Dr. Matthew O. Leavitt. The company reports 40% of the U.S. outpatient prostate cancer market and 180% annual volume growth. Leavitt will serve a three-year volunteer term in Romania.EIN PresswireLumea Partners with Primaa to Expand Dermatopathology Offerings with Cleo Skin AILumea, a U.S. leader in primary clinical digital pathology, has partnered with Primaa to integrate Primaa's Cleo Skin AI solution into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin is the first AI tool worldwide designed specifically to assist in diagnosing the four most common skin lesions, offering automated triage, sub-millimeter measurements, and biomarker detection. The open marketplace integration allows labs to adopt the technology without changing their existing LIS or scanning hardware, expanding Lumea's diagnostic ecosystem for dermatology groups.Clinical Lab ProductsDigital Pathology Adoption Remains Limited in US Despite Growing InterestA new KLAS Research report found that fewer than 15% of US healthcare organizations have selected a digital pathology vendor, placing US adoption in early stages despite FDA clearances and growing interest. The report highlights that pathology-specific vendors such as Proscia, PathAI, and LUMEA receive higher customer satisfaction than traditional imaging vendors, while Leica Biosystems dominates the scanner market with its FDA-cleared Aperio GT 450 DX. The report also notes strong and growing interest in AI applications for digital pathology, particularly for breast and prostate cancer algorithms, with breast cancer biomarker assessment generating the most interest.The Courier-JournalLumea and Voicebrook Announce Strategic Partnership to Advance Digital Pathology WorkflowsLumea and Voicebrook announced a strategic partnership to enhance digital pathology workflows, integrating Voicebrook's VoiceOver PRO platform with Lumea's pathology systems to support hands-free documentation, imaging, and reporting. The integration aims to streamline pathology processes, improve efficiency, and facilitate digital adoption in laboratories.